Tin tức & Cập nhật
Xem bài viết Ung thư
Xem
1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL
The final results of the CLL14 trial validate the long-term efficacy of 1-year fixed-duration venetoclax plus obinutuzumab in previously untreated patients with chronic lymphocytic leukaemia (CLL) and co-existing conditions.
1-year fixed-duration venetoclax-obinutuzumab goes a long way in CLL
10 Jul 2026
GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
Updates from the GARNET trial underpin dostarlimab monotherapy as a meaningful treatment option for women with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) advanced/recurrent endometrial cancer (A/R EC) who progressed after prior platinum therapy.
GARNET updates confirm long-term dostarlimab benefit in dMMR/MSI-H endometrial cancer
09 Jul 2026
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
A novel oral formulation of paclitaxel, DHP107, is noninferior to weekly intravenous (IV) paclitaxel in the treatment of HER2-negative recurrent or metastatic breast cancer, as shown by the results of the phase III OPTIMAL study.
Oral paclitaxel on par with IV formulation in HER2-negative breast cancer
08 Jul 2026
MonumenTAL-3 supports talquetamab–daratumumab ± pomalidomide for RRMM
In the phase III MonumenTAL-3 trial, talquetamab plus daratumumab (Tal-D), with or without pomalidomide, shows substantial efficacy in the treatment of relapsed/refractory multiple myeloma (RRMM), compared with daratumumab, pomalidomide, and dexamethasone (DPd).
